A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Annals of the Rheumatic Diseases

Volumn 76, Issue 8, 2017, Pages 1426-1431

  Glintborg, Bente ^a,b   Sørensen, Inge Juul ^a,c   Loft, Anne Gitte ^d   Lindegaard, Hanne ^e   Linauskas, Asta ^f   Hendricks, Oliver ^g   Hansen, Inger Marie Jensen ^h   Jensen, Dorte Vendelbo ^a,b   Manilo, Natalia ⁱ   Espesen, Jakob ^j   Klarlund, Mette ^k   Grydehøj, Jolanta ^l   Dieperink, Sabine Sparre ^a   Kristensen, Salome ^m   Olsen, Jimmi Sloth ⁿ   Nordin, Henrik ^o   Chrysidis, Stavros ^p   Dalsgaard Pedersen, Dorte ^q   Sørensen, Michael Veedfald ^r   Andersen, Lis Smedegaard ^s   Grøn, Kathrine Lederballe ^a   Krogh, Niels Steen ^t   Pedersen, Lars ^d   Hetland, Merete Lund ^a,c   more..

^a University of Copenhagen   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f NORTH DENMARK REGIONAL HOSPITAL   (Denmark)

^g King Christian the Xth Hospital   (Denmark)

^h SVENDBORG HOSPITAL   (Denmark)

ⁱ FREDERIKSBERG HOSPITAL   (Denmark)

^j LILLEBAELT HOSPITAL   (Denmark)

^k HILLERØD HOSPITAL   (Denmark)

^l HOLSTEBRO HOSPITAL   (Denmark)

^m AALBORG UNIVERSITY HOSPITAL   (Denmark)

ⁿ SILKEBORG REGIONAL HOSPITAL   (Denmark)

^o ZEALAND UNIVERSITY HOSPITAL   (Denmark)

^p Esbjerg University Hospital   (Denmark)

^q VIBORG HOSPITAL   (Denmark)

^r HORSENS REGIONAL HOSPITAL   (Denmark)

^s Rønne Hospital   (Denmark)

^t Zitelab Aps   (Denmark)

more..

Author keywords

Ankylosing Spondylitis; Anti TNF; Outcomes research; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; INFLIXIMAB DYYB; METHOTREXATE; ANTIRHEUMATIC AGENT; BIOSIMILAR AGENT; CT-P13; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DANISH CITIZEN; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DISEASE REGISTRY; DRUG EFFICACY; DRUG RETENTION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SPONDYLARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; DENMARK; DRUG SUBSTITUTION; MIDDLE AGED; REGISTER; SPONDYLARTHROPATHIES;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; DENMARK; DRUG SUBSTITUTION; FEMALE; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; REGISTRIES; SPONDYLARTHROPATHIES; TREATMENT OUTCOME;

EID: 85020798557     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210742     Document Type: Article

References (21)

1. Dörner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 2016;75:974-82.
2. P ark W, Yoo DH, Jaworski J, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther 2016;18:25.
3. Yoo DH, Racewicz A, Brzezicki J, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther 2016;18:82.
4. T he danish regions, RADS, guidelines for use of biosimilar infliximab and etanercept. http://www. regioner. dk/ media/ 3488/ rads-notat-om-anvendelsen-af-biosimilaere-juni-2016. pdf (Accessed Jan 2017).
5. Brodszky V, Baji P, Balogh O, et al. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ 2014;15(S1):65-71.
6. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis 2017;76:355-63.
7. P ark W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 2017;76:346-54.
8. Abdalla A, Byrne NE, Conway R, et al. THU0120 Long Term Safety and Efficacy of Biosimilar Infliximab among Patients with Inflammatory Arthritis Switched from Reference Product: Table 1. Ann Rheum Dis 2016;75(Suppl 2):223.2-223.
9. N ikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from remicade (infliximab) in patients with established rheumatic disease. report of clinical experience based on prospective observational data. Expert Opin Biol Ther 2015;15:1677-83.
10. Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol 2015;30:1705-12.
11. Kang YS, Moon HH, Lee SE, et al. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci 2015;60:951-6.
12. Buer LC, Moum BA, Cvancarova M, et al. Switching from INX(R) to CT-P13(R) is safe and feasible: a prospective, open-label study. J Crohns Colitis 2016. EPUB ahead of print.
13. Gentileschi S, Barreca C, Bellisai F, et al. Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseasesResponse to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677-1683.
14. Expert Opin Biol Ther 2016;16:1311-2.
15. Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared to maintained treatment with originator infliximab (NOR-SWITCH): a 52-week randomised double-blind non-inferiority trial. Lancet 2017 (Accepted for publication).
16. I bfelt EH, Jensen DV, Hetland ML. The danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO. Clin Epidemiol 2016;8:737-42.
17. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
18. S mits LJ, Derikx LA, de Jong DJ, et al. Clinical outcomes following a switch from remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis 2016;10:1287-93. EPUB ahead of print.
19. Glintborg B, Kringelbach TM, Høgdall E, et al. Non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis-impact on s-infliximab and antidrug-antibodies. Results from the Danish Rheumatologic Biobank and the DANBIO registry. Abstract. Arthritis Rheumatol 2016;68(suppl 10).
20. P lanès S, Villier C, Mallaret M. The nocebo effect of drugs. Pharmacol Res Perspect 2016;4:e00208.
21. Favalli EG, Pregnolato F, Biggioggero M, et al. Twelve-Year retention rate of First-Line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry. Arthritis Care Res 2016;68:432-9.